[
  {
    "ts": null,
    "headline": "Are High-Yield Dividend Stocks Best for Income-Focused Investors?",
    "summary": "Dividends come with many clear benefits, including a passive income stream and a shield against drawdowns in other positions.",
    "url": "https://finnhub.io/api/news?id=cdf431b26e840376c1ed4a347b7e1e05d545e53f81166debba7e988880a82b79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741647840,
      "headline": "Are High-Yield Dividend Stocks Best for Income-Focused Investors?",
      "id": 133184450,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dividends come with many clear benefits, including a passive income stream and a shield against drawdowns in other positions.",
      "url": "https://finnhub.io/api/news?id=cdf431b26e840376c1ed4a347b7e1e05d545e53f81166debba7e988880a82b79"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson - Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis",
    "summary": "SPRING HOUSE - Johnson & Johnson today announced new icotrokinra data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis seeking...",
    "url": "https://finnhub.io/api/news?id=3263c10710231cbb6e510e225c0f7e187192b181425afcabeb46997b9c6a3312",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741610360,
      "headline": "Johnson & Johnson - Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis",
      "id": 133122064,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "SPRING HOUSE - Johnson & Johnson today announced new icotrokinra data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis seeking...",
      "url": "https://finnhub.io/api/news?id=3263c10710231cbb6e510e225c0f7e187192b181425afcabeb46997b9c6a3312"
    }
  },
  {
    "ts": null,
    "headline": "Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option",
    "summary": "Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option",
    "url": "https://finnhub.io/api/news?id=951910a318b37d2a9dc926640a43045d151550e30e14b359ca9b482011190688",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741604460,
      "headline": "Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option",
      "id": 133123584,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option",
      "url": "https://finnhub.io/api/news?id=951910a318b37d2a9dc926640a43045d151550e30e14b359ca9b482011190688"
    }
  },
  {
    "ts": null,
    "headline": "Genmab Stops Blood Cancer Treatment Development After J&J Won't License It",
    "summary": "Genmab Stops Blood Cancer Treatment Development After J&J Won't License It",
    "url": "https://finnhub.io/api/news?id=d6579e85e922701d5f72dc097b5e0086e106434b9f454af1bbdbc2d21020e599",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741603380,
      "headline": "Genmab Stops Blood Cancer Treatment Development After J&J Won't License It",
      "id": 133118688,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Genmab Stops Blood Cancer Treatment Development After J&J Won't License It",
      "url": "https://finnhub.io/api/news?id=d6579e85e922701d5f72dc097b5e0086e106434b9f454af1bbdbc2d21020e599"
    }
  },
  {
    "ts": null,
    "headline": "Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out",
    "summary": "Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out",
    "url": "https://finnhub.io/api/news?id=a55d7493fb58c6cf6d7bc37bd29ce2e81811d28363bf7b4f62e782336c9cd1f8",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741601986,
      "headline": "Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out",
      "id": 133118668,
      "image": "",
      "related": "JNJ",
      "source": "DowJones",
      "summary": "Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out",
      "url": "https://finnhub.io/api/news?id=a55d7493fb58c6cf6d7bc37bd29ce2e81811d28363bf7b4f62e782336c9cd1f8"
    }
  },
  {
    "ts": null,
    "headline": "Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer",
    "summary": "Phase 3 MARIPOSA study showed LAZCLUZE® plus RYBREVANT® significantly improved progression-free survival, reducing the risk of disease progression or death by 30 per cent versus osimertinib...",
    "url": "https://finnhub.io/api/news?id=a18a1d916d5b5a20ae67ae3e072fd84881df862fedc23ae9526e541f23fd9428",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741595495,
      "headline": "Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer",
      "id": 133117068,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Phase 3 MARIPOSA study showed LAZCLUZE® plus RYBREVANT® significantly improved progression-free survival, reducing the risk of disease progression or death by 30 per cent versus osimertinib...",
      "url": "https://finnhub.io/api/news?id=a18a1d916d5b5a20ae67ae3e072fd84881df862fedc23ae9526e541f23fd9428"
    }
  },
  {
    "ts": null,
    "headline": "Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients",
    "summary": "Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC...",
    "url": "https://finnhub.io/api/news?id=9d21abf98acb3fd9991a31bd067c06682794865728b84a8ee7a8a4ec4d1a6dbc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741593674,
      "headline": "Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients",
      "id": 133116892,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC...",
      "url": "https://finnhub.io/api/news?id=9d21abf98acb3fd9991a31bd067c06682794865728b84a8ee7a8a4ec4d1a6dbc"
    }
  }
]